welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Safety Study of BLS-M22 in Healthy Volunteers
study id #: NCT03789734
condition: Muscular Dystrophy, Duchenne
status: not yet recruitingpurpose:
BLS-M22 is being developed as an anti-myotatin agent for the treatment of Duchenne Muscular Dystrophy (Muscular Dystrophy). A total of 37 subjects participated in this study to confirm the safety of BLS-M22.
intervention: BLS-M22, Placebo
mechanism of action: Anti-myostatin to promote muscle growth
last updated: January 16, 2019
start date: March 2019
estimated completion: October 2019
phase of development: Phase 1
size / enrollment: 37
This study is a dose Block-randomized, Double-blind, Placebo-controlled and Dose-escalation Phase I Clinical Trial to Evaluate Safety of BLS-M22.
The single ascending dose group participated in 9 patients in each group(500mg, 1000mg, 2000mg/BLS-M22 or Placebo(n=7:2)). The multiple ascending dose group participated in 10 patients(determined dose in SAD/BLS-M22 or Placebo(n=8:2)).
- Adverse events [ Time Frame: up to 4-5 weeks ]
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- AUClast [ Time Frame: From 0 hours to 24 hours ]
Evaluation of the pharmacokinetic properties after administration of BLS-M22
- Immunogenicity(Myostatin specific IgG level in serum) [ Time Frame: up to 4-5 weeks ]
Evaluation of the immunogenicity after administration of BLS-M22
• Male and female subjects between 19-55 years of age
• BMI: 19~28kg/m2(male), 18~25kg/m2(female) at screening test
• Able to provide consent to participate and having signed an Informed Consent Form (ICF)
• The subjects can obey the demands of the scheme
• Subject has a clinically significant disease or history of liver, kidney, cardiovascular system, endocrine system, musculoskeletal system, digestive system, respiratory system, neuropsychiatry, blood tumor system.
• Hypersensitive to the lactobacillus-containing food (such as yogurt) and the lactobacillus preparation and the investigational drug
• Subject has received an investigational drug or a bioequivalence study drug within 90 days of the randomization
• Subject has received steroids or other immunosuppressive drugs within 30 days of randomization
• Positive serum test results for hepatitis C virus, hepatitis B virus, HIV or syphilis
• Those who do not use of a medically acceptable method of contraception during the trial, or who plan to provide sperm
• Pregnant women
• Subject has genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
• Subject has abnormal clinical laboratory test results
• Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study
Givinostat in Duchenne’s Muscular Dystrophy Long-term Safety and Tolerability StudyThis is an open label, long-term safety,...
Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMDThe purpose of this study is to determin...
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrop...it is a randomised, double blind, parall...
An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular DystrophyThis study is an open-label extension to...
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne M...This is a Phase 2 randomized, 2-period, ...
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
Extension Study of ACE-031 in Subjects With Duchenne Muscular DystrophyTo evaluate the long-term safety and tol...
BIOPHYTIS receives orphan drug designation in the United States for Sarconeos in Duchenne muscular dystrophy (DMD)BIOPHYTIS, a biotechnology company speci...
BIOPHYTIS to Host Key Opinion Leader Meeting on the Biology of Aging and its Application in Neuromuscular DiseasesBiophytis, a clinical-stage biotechnolog...
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017We issued an updated research report on ...